NO20060535L - Aztreonam-L-lysin og fremgangsmater for fremstilling av dette - Google Patents

Aztreonam-L-lysin og fremgangsmater for fremstilling av dette

Info

Publication number
NO20060535L
NO20060535L NO20060535A NO20060535A NO20060535L NO 20060535 L NO20060535 L NO 20060535L NO 20060535 A NO20060535 A NO 20060535A NO 20060535 A NO20060535 A NO 20060535A NO 20060535 L NO20060535 L NO 20060535L
Authority
NO
Norway
Prior art keywords
aztreonam
lysine
preparing
methods
lysine salt
Prior art date
Application number
NO20060535A
Other languages
English (en)
Other versions
NO333985B1 (no
Inventor
Claude Singer
Csaba Szabo
Viktor Gyollai
Istvan Bodi
Original Assignee
Teva Pharmaceutical Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Usa Inc filed Critical Teva Pharmaceutical Usa Inc
Publication of NO20060535L publication Critical patent/NO20060535L/no
Publication of NO333985B1 publication Critical patent/NO333985B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen angår L-lysinsaltet av aztieonam og fremgangsmåter for fremstilling av L-lysinsaltet av aztreonam.
NO20060535A 2003-07-02 2006-02-01 Fremgangsmåte for fremstilling av aztreonam-L-lysin NO333985B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48486103P 2003-07-02 2003-07-02
US55009804P 2004-03-04 2004-03-04
PCT/US2004/021237 WO2005005424A1 (en) 2003-07-02 2004-07-01 Aztreonam l-lysine and methods for the preparation thereof

Publications (2)

Publication Number Publication Date
NO20060535L true NO20060535L (no) 2006-02-01
NO333985B1 NO333985B1 (no) 2013-11-04

Family

ID=34068199

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060535A NO333985B1 (no) 2003-07-02 2006-02-01 Fremgangsmåte for fremstilling av aztreonam-L-lysin

Country Status (10)

Country Link
US (2) US7262293B2 (no)
JP (1) JP4741487B2 (no)
AU (1) AU2004256124B2 (no)
BR (1) BRPI0411691A (no)
CA (2) CA2733145C (no)
DE (1) DE112004001191B4 (no)
ES (1) ES2304078B2 (no)
IL (1) IL172802A (no)
NO (1) NO333985B1 (no)
WO (1) WO2005005424A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231244B2 (en) * 2000-12-27 2006-06-29 Gilead Sciences, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
EP1527072A1 (en) * 2002-08-05 2005-05-04 Teva Gyogyszergyar Reszvenytarsasag Preparation of aztreonam
EP1622900A1 (en) * 2003-05-15 2006-02-08 Teva Gyogyszergyar Reszvenytarsasag Aztreonam beta-polymorph with very low residual solvent content
WO2005005424A1 (en) * 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
MX2007000526A (es) * 2005-05-09 2007-03-28 Sicor Inc Proceso para elaborar aztreonam.
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923998A (en) * 1977-03-14 1990-05-08 Fujisawa Pharmaceutical Company, Ltd. Cephem and cepham compounds and processes for preparation thereof
US4775670A (en) * 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4946838A (en) * 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4652651A (en) * 1983-05-31 1987-03-24 Hoffmann-La Roche Inc. Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid intermediates via catalytic ester cleavage
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4675398A (en) 1985-08-16 1987-06-23 E. R. Squibb & Sons, Inc. Copper-mediated oximation reaction
CA1339136C (en) * 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
JP2653856B2 (ja) * 1988-11-08 1997-09-17 科学技術振興事業団 アミノ酸過酸化物の測定方法及び測定装置
US5254681A (en) * 1989-08-02 1993-10-19 Consiglio Nazionale Delle Ricerche Process for preparing monobactames and their intermediate product
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
PL165700B1 (pl) 1991-10-15 1995-01-31 Pan Sposób wytwarzania kwasu 32/2-amtnotiazoiilo-4/-2/1 -t-butoksykarbonylo- 1 -metyloetoksylmino/octowego
DE19652284A1 (de) * 1996-12-16 1998-06-18 Hoechst Schering Agrevo Gmbh Neue Gene codierend für Aminosäure-Deacetylasen mit Spezifität für N-Acetyl-L-Phosphinothricin, ihre Isolierung und Verwendung
AU4143200A (en) * 1999-04-27 2000-11-10 Masayoshi Nanba Human cell line showing stable expression of cytochromes p450
JP4320922B2 (ja) * 1999-06-04 2009-08-26 住友化学株式会社 エステラーゼ遺伝子及びその利用
AU1572101A (en) 1999-11-08 2001-06-06 Pharmacia & Upjohn Company Admixture of linezolid and other antibacterial agents
AUPQ872300A0 (en) * 2000-07-11 2000-08-03 Praxis Pharmaceuticals Pty Ltd Compounds and methods
AU2002231244B2 (en) * 2000-12-27 2006-06-29 Gilead Sciences, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
SK652004A3 (en) * 2001-06-29 2004-09-08 Lundbeck & Co As H Heteroaryl derivatives, pharmaceutical composition with the content thereof and use of the same
CN1545514A (zh) 2001-08-27 2004-11-10 阿拉宾度药业有限公司 β型晶体无水氨曲南的生产方法
BR0212522A (pt) * 2001-09-14 2004-08-10 Novo Nordisk As Ligando de ligação de zinco, hexâmero de insulina, preparação aquosa de insulina e métodos de prolongar a ação de uma preparação de insulina e de preparar um ligando de ligação de zinco
DE50212771D1 (de) * 2001-10-17 2008-10-23 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
MXPA04004219A (es) * 2001-11-03 2004-09-10 Astrazeneca Ab Derivados de quinazolina como agentes antitumorales.
PT1443937E (pt) * 2001-11-13 2008-09-23 Ortho Mcneil Janssen Pharm 1,4-benzodiazepinas substituídas e as suas utilizações para o tratamento de cancro
EP1527072A1 (en) * 2002-08-05 2005-05-04 Teva Gyogyszergyar Reszvenytarsasag Preparation of aztreonam
EP1413603A1 (en) 2002-10-25 2004-04-28 Titecs Japan Corporation Vibration-damping material composition
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
AU2002356646A1 (en) 2002-12-11 2004-06-30 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
EP1622900A1 (en) * 2003-05-15 2006-02-08 Teva Gyogyszergyar Reszvenytarsasag Aztreonam beta-polymorph with very low residual solvent content
WO2005005424A1 (en) * 2003-07-02 2005-01-20 TEVA Gyógyszergyár Részvénytársaság Aztreonam l-lysine and methods for the preparation thereof

Also Published As

Publication number Publication date
NO333985B1 (no) 2013-11-04
JP2007521306A (ja) 2007-08-02
WO2005005424A1 (en) 2005-01-20
ES2304078B2 (es) 2009-09-16
IL172802A (en) 2011-10-31
CA2733145C (en) 2012-06-19
WO2005005424B1 (en) 2005-04-14
JP4741487B2 (ja) 2011-08-03
ES2304078A1 (es) 2008-09-01
CA2733145A1 (en) 2005-01-20
US20070167424A1 (en) 2007-07-19
AU2004256124B2 (en) 2011-04-28
BRPI0411691A (pt) 2006-12-26
DE112004001191B4 (de) 2017-11-09
CA2531170C (en) 2011-05-10
CA2531170A1 (en) 2005-01-20
US7358093B2 (en) 2008-04-15
US7262293B2 (en) 2007-08-28
DE112004001191T5 (de) 2009-04-23
US20050032775A1 (en) 2005-02-10
AU2004256124A1 (en) 2005-01-20
IL172802A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DK1896006T3 (da) Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
NO20092609L (no) Tannate salt of rasagiline
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE557021T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
EA200801372A1 (ru) Способы получения замещенных пиримидинов
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602005019899D1 (de) System zur behandlung von ischämischem schlaganfall
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
IL185031A0 (en) Method for the preparation of pregabalin and salts thereof
TW200716525A (en) Process for preparation of sulfamide derivatives
NO20055741L (no) Nye kjemiske forbindelser
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
NO20072473L (no) Fremgangsmate for fremstilling av kinolinforbindelser og oppnadde produkter
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
EA200701852A1 (ru) Производные аминокислот
UA96269C2 (uk) Інгібітори цистеїнпротеази та їх терапевтичне застосування
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen